BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 27,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 27,000 shares of the stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00. Following the completion of the transaction, the chief executive officer owned 314,209 shares in the company, valued at $31,009,286.21. This represents a 7.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total transaction of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00.

BioNTech Trading Up 0.6%

Shares of BioNTech stock traded up $0.56 during trading on Monday, hitting $99.08. 777,945 shares of the company were exchanged, compared to its average volume of 1,094,445. The firm has a market capitalization of $25.06 billion, a P/E ratio of -12.65 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The firm’s fifty day moving average price is $98.17 and its 200 day moving average price is $94.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s revenue was down 59.5% compared to the same quarter last year. During the same period last year, the company earned ($1.60) earnings per share. As a group, sell-side analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently bought and sold shares of the company. Engineers Gate Manager LP lifted its position in BioNTech by 17.3% during the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock worth $1,157,000 after buying an additional 1,833 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of BioNTech during the 2nd quarter worth about $39,000. Nykredit A S bought a new position in shares of BioNTech in the 2nd quarter valued at about $293,000. B. Metzler seel. Sohn & Co. AG increased its position in shares of BioNTech by 66.7% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock valued at $1,020,000 after acquiring an additional 4,390 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of BioNTech in the second quarter valued at about $2,520,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

BNTX has been the subject of several research analyst reports. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $128.00 to $105.00 in a report on Tuesday, September 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Finally, Morgan Stanley dropped their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.